Académique Documents
Professionnel Documents
Culture Documents
(2015) 1e7
Clinical Research
ABSTRACT
RESUM
E
rielle pe
riphe
rique
Introduction : Les patients atteints dune maladie arte
s par une claudication intermittente dans la distance
(MAP) sont limite
te
de
montre
que lors de maladie coroquils peuvent parcourir. Il a e
riode dexercice avant que napparnarienne lallopurinol prolonge la pe
vention des pertes doxygne dans
aisse langine, probablement par la pre
duction des effets ne
fastes du stress oxydatif.
les tissus et la re
thodes : Dans cette e
tude, nous avons e
value
si lallopurinol
Me
e avant la manifestation de la douleur la
pourrait prolonger la dure
jambe chez les participants atteints de MAP. Les participants dun
partition ale
atoire et double insu e
taient re
partis
essai clinique re
atoire pour recevoir soit lallopurinol raison de 300
de manire ale
bo durant 6 mois. Le principal critre de
mg 2 fois par jour ou le place
tait la modication de la capacite
deffort le
preuve de
jugement e
taient la
marche sur tapis roulant 6 mois. Les critres secondaires e
distance de marche en 6 minutes, le Walking Impairment Question-
Received for publication April 13, 2015. Accepted May 14, 2015.
Corresponding author: Dr Alan J. Robertson, Division of Cardiovascular
and Diabetes Medicine, Mailbox 2, University of Dundee, Ninewells Hospital
and Medical School, Dundee DD1 9SY, United Kingdom. Tel.: 44 (0)
1382-632180.
E-mail: alanrobertson@nhs.net
See page 6 for disclosure information.
http://dx.doi.org/10.1016/j.cjca.2015.05.010
0828-282X/ 2015 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
39 of 50 (78%) male.
Results: Five participants withdrew during the study (2 active, 3 placebo). There was a signicant reduction in uric acid levels in those who
received active treatment of 52.1% (P < 0.001), but no signicant
change in either the pain-free or the maximum walking distance. Other
measures of exercise capacity, blood vessel function, and the participants own assessment of their health and walking ability also did not
change during the course of the study.
Conclusions: Although allopurinol has been shown to be of benet in a
number of other diseases, in this study there was no evidence of any
improvement after treatment in patients with PAD.
die
e par le ux et les
naire, le questionnaire SF-36, la dilatation me
s lipoprote
ines de faible densite
. Les mesures des re
sultats
oxyde
taient re
pe
te
es la mi-e
tude et la n de le
tude. Cinquante pare
taient des hommes avaient un ge moyen
ticipants dont 39 (78 %) e
de 68,4 1,2 ans.
sultats : Cinq participants se sont retire
s durant le
tude (2 du
Re
bo). Une re
duction
groupe sous traitement actif, 3 du groupe sous place
signicative des concentrations en acide urique de 52,1 % (P < 0,001)
te
observe
e chez ceux qui recevaient le traitement actif, mais aucun
ae
te
observe
dans la distance de marche
changement signicatif na e
deffort,
sans douleur ou maximale. Les autres mesures de la capacite
valuation des
le fonctionnement des vaisseaux sanguins et la propre e
et leur habilete
la marche nont
participants concernant leur sante
galement pas change
au cours de le
tude.
e
te
de
montre
que lallopurinol est
Conclusions : Bien quil ait e
ne
que contre plusieurs autres maladies, cette e
tude na montre
be
lioration aprs le traitement chez les patients
aucune preuve dame
atteints de MAP.
Methods
This study was a randomized, double-blind parallel-group
placebo-controlled clinical trial, run in accordance with the
Declaration of Helsinki and The Medicines for Human Use
(Clinical Trials) (Amendment) Regulations, 2006. Approvals
were received from local National Health Service (NHS)
Research and Development, Scotland A Research Ethics
Exclusion
Men and women age 35-85 years of age who suffer from PAD
PAD dened as:
B Claudication dened as leg pain with walking that disappears within 10 minutes with standing and of presumed atherosclerotic origin and
B An ankle brachial pressure index of < 0.90 on the worst leg at rest
Stable disease demonstrated by a reproducible pain-free walking distance on 2 consecutive treadmill tests (ie, less than 25% variance)
The reason for termination of the test must be claudication pain only
Rest pain
Childbearing potential without adequate contraceptive measures
Heart failure or any other exercise-limiting cardiac disease
Blood pressure > 180/100 mm Hg
Renal or liver disease
Malignancy
Already receiving allopurinol or had an adverse reaction to it
Recent marked change in symptoms or recent (in the past 6 months) intervention for PAD
Receiving treatment with either 6-mercaptopurine, azathioprine, warfarin, or theophylline
139.7 (95% CI, 96.2-183.2) and 146.1 (95% CI, 111.8180.3), respectively (P 0.34). Subdivision into the distance,
speed, and climb elements showed similar results.
Baseline SF-36 scores were 535.1 (95% CI, 457.7-612.5)
in the allopurinol group and 571.0 (95% CI, 519.5-622.4) in
the placebo group (P 0.73). Values at the nal visit were
555.2 (95% CI, 485.0-625.5) and 536.5 (95% CI, 470.8602.2), respectively (P 0.57). Analysis of the various subdomains of SF-36 also showed no signicant difference.
Baseline Ox-LDL values were 53.0 U/L in the allopurinol
group (95% CI, 45.7-60.3) and 49.4 U/L (95% CI, 43.155.8) in the placebo group (P 0.62). These did not
signicantly change during the course of the study.
There was 1 serious adverse event (community-acquired
pneumonia requiring hospital admission). No signicant
changes in urea and electrolytes or liver function tests were
noted in the course of the study in either group.
69.6
21
1.69
77.7
27.2
76.5
31.7
153
76
0.61
7.4
(9.1)
(84)
(0.09)
(16.6)
(5.1)
(11.6)
(21.0)
(21)
(11)
(0.12)
(10.0)
Placebo
(n 25)
67.3
18
1.66
80.6
29.1
75.4
49.7
156
79
0.60
16.8
(7.5)
(72)
(0.07)
(16.6)
(5.2)
(14.9)
(37.0)
(20)
(10)
(0.12)
(18.8)
6
19
0.36 (0.09)
7
18
0.34 (0.09)
0.75
0.98
24 (96)
23 (92)
17 (68)
23 (92)
24 (96)
18 (72)
0.88
0.88
0.87
Discussion
There was no signicant difference in baseline COD and
PWD measurements in the placebo group (despite a greater
pack-year history in this group). By the end of the study both
measures had increased in each arm of the studydthis was on the
order of 40 m for COD and 27 m for PWD, again with no
signicant difference between active and placebo groups. This
temporal increase in walking distance in the placebo arm is
something that has been recognized previously in studies of
PAD.25 To investigate if there was any subgroup that showed
benet from allopurinol, the treadmill results were split into
those with high/low baseline COD/PWD and those with high/
low baseline uric acid/systolic blood pressure and ankle-brachial
index (see Supplementary Material). None of these subdivisions
changed the results and there remained no statistically signicant
difference between the 2 groups after 6 months of treatment.
In consideration of the FMD results, it can be seen that the
baseline values were similar in the active and placebo groups.
The relative change in vessel diameter after hyperemia (ie,
Time point
COD baseline
COD visit 4
COD visit 6
PWD baseline
PWD visit 4
PWD visit 6
137.1
161.7
180.0
315.5
320.1
347.4
(82.0-192.2)
(109.0-214.3)
(111.5-248.6)
(206.0-425.0)
(209.0-431.2)
(224.8-470.0)
(105.4-198.0)
(110.2-200.0)
(133.1-221.2)
(266.4-458.8)
(256.9-426.1)
(253.9-462.9)
P
0.31
0.95
0.48
0.24
0.42
0.61
Figure 2. Reduction in uric acid (vertical bars indicate 95% condence interval).
Time point
Baseline
Visit 4
Visit 6
Mean change from
baseline to Visit 4
Mean change from
baseline to Visit 6
401.2
396.3
398.2
4.4
(371.7-430.7)
(366.1-426.6)
(374.4-422.1)
(10.5 to 19.4)
(369.2-409.1)
(376.3-414.8)
(375.8-424.0)
(2.4-19.8)
13.1 (1.0-25.1)
P
0.72
0.97
0.92
0.73
0.63
Table 5. Flow-mediated dilatation: baseline vessel diameter and percentage change throughout study
Time point
Baseline vessel size prior to cuff ination, mm
Absolute change post-cuff at visit 2 (initial visit), mm
Relative change post-cuff at visit 2 (initial visit), mm
Absolute change post-cuff at visit 5, mm
Relative change post-cuff at visit 5, %
Relative change compared with baseline post-cuff at visit 5, %
Absolute change post-cuff at visit 6, mm
Relative change post-cuff at visit 6, %
Relative change compared with baseline post-cuff at visit 6, %
(4.34-4.98)
(0.25-0.51)
(5.87-10.79)
(0.16-0.31)
(3.46-6.24)
(0.53 to 0.06)
(0.30-0.52)
(6.43-11.40)
(0.30 to 1.11)
(3.75-4.73)
(0.19-0.50)
(4.92-14.30)
(0.13-0.34)
(3.54-7.69)
(0.59 to 0.28)
(0.14-0.36)
(3.49-9.61)
(0.64 to 0.09)
P
0.14
0.65
0.84
0.66
0.32
0.42
0.06
0.27
0.32
Post-cuff indicates the measurement of maximal vessel size that was made immediately following deation of the blood pressure cuff.
CI, condence interval.
18. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaluation of walking
impairment by questionnaire in patients with peripheral arterial disease.
J Vasc Med Biol 1990;2:142-58.
3. Fowkes F, Housley E, Cawood E, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the
general population. Int J Epidemiol 1991;20:384-92.
19. Regensteiner JG, Gardner A, Hiatt WR. Exercise testing and exercise
rehabilitation for patients with peripheral arterial disease: status in 1997.
Vasc Med 1997;2:147-55.
20. Ware JE. SF-36 Health Survey: Manual and Interpretation Guide.
Lincoln, RI: QualityMetric Inc, 2000.
Supplementary Material
To access the supplementary material accompanying this
article, visit the online version of the Canadian Journal of
Cardiology at www.onlinecjc.ca and at http://dx.doi.org/10.
1016/j.cjca.2015.05.010.